As our results demonstrate that these vaccines are more effective in a preventative setting, it may be viable to utilize these vaccines early after prostate cancer diagnosis, in combination with standard-of-care treatment to immunologically stimulate responses as well as prevent the emergence of resistance, through the immune targeting of AR-V7 and other isoforms. The gene discussed is AR; the disease is Familial prostate cancer.